Postoperative Nausea and Vomiting (PONV) Management Market
Market Insights on Postoperative Nausea and Vomiting (PONV) Management covering sales outlook, demand forecast & up-to-date key trends
Postoperative Nausea and Vomiting (PONV) Management Market by Treatment Type, Distribution Channel & Region | Forecast 2023 to 2033
Postoperative Nausea and Vomiting (PONV) Management Market Snapshot
The global postoperative nausea and vomiting (PONV) management market garnered a market value of US$ 1.04 Billion in 2022 and is expected to accumulate a market value of US$ 3.9 Billion by registering a CAGR of 12.8% in the forecast period 2023 to 2033. Growth of the postoperative nausea and vomiting (PONV) management market can be attributed to increasing number of surgeries being performed and the growing awareness of the importance of managing PONV for patient comfort and safety. The market for postoperative nausea and vomiting (PONV) management registered a CAGR of 7.4% in the historical period 2018 to 2022
Postoperative nausea and vomiting (PONV) management refers to the various strategies and interventions used to prevent or treat nausea and vomiting in patients after surgery. PONV is a common side effect of anesthesia and surgery, affecting up to 80% of patients in some cases. It can cause discomfort, dehydration, electrolyte imbalances, and delayed recovery.
PONV management typically involves a combination of pharmacological and non-pharmacological interventions, such as antiemetic medications, IV fluids, and the use of acupressure or acupuncture. Effective PONV management is essential for patient comfort and recovery after surgery, and can also help prevent complications such as aspiration pneumonia and wound dehiscence.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 1.17 Billion |
|
Anticipated Forecast Value (2033) |
US$ 3.9 Billion |
|
Projected Growth Rate (2023 to 2033) |
12.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Postoperative Nausea and Vomiting (PONV) Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Postoperative nausea and vomiting (PONV) management reflected a value of 7.4% during the historical period, 2018 to 2022.
The PONV management market has been growing steadily in recent years due to several factors, including an increasing number of surgeries being performed worldwide, growing awareness of the importance of PONV management for patient comfort and safety, and the development of new and effective antiemetic medications.
Several factors are driving the growth of the PONV management market, including the increasing prevalence of PONV, the development of new and effective antiemetic medications, and the adoption of non-pharmacological approaches to PONV management.
Thus, the market for postoperative nausea and vomiting (PONV) management is expected to register a CAGR of 12.8% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Postoperative Nausea and Vomiting (PONV) Management Market?
Increasing number of surgeries driving growth of PONV market
The growing number of surgeries being performed globally is a key driver of the PONV management market. As the number of surgeries increases, the incidence of PONV also rises, leading to a greater demand for effective PONV management solutions.
The development of new and more effective antiemetic medications is another important driver of the PONV management market. These medications can provide better control of PONV symptoms, resulting in improved patient outcomes and satisfaction.
Healthcare providers are increasingly aware of the importance of managing PONV for patient comfort and safety. This has led to greater adoption of PONV management protocols and the use of a range of pharmacological and non-pharmacological interventions.
The development of new technologies, such as electronic stimulation devices, has expanded the range of PONV management solutions available to healthcare providers. These technologies provide non-pharmacological options that can be used in conjunction with antiemetic medications to improve PONV management outcomes.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystAvailability of treatments shaping landscape for PONV market
Pharmacological Interventions
Antiemetic Medications: Antiemetic medications are the most commonly used pharmacological intervention for PONV management. These medications work by blocking specific receptors in the brain that are responsible for inducing nausea and vomiting. Some of the commonly used antiemetic medications include ondansetron, dexamethasone, and metoclopramide.
Anesthetic Technique: The choice of anesthetic technique used during surgery can also impact the incidence of PONV. Regional anesthesia, such as spinal or epidural anesthesia, has been shown to be associated with a lower incidence of PONV compared to general anesthesia.
Non-Pharmacological Interventions
Acupuncture: Acupuncture involves the insertion of fine needles into specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Acupressure: Acupressure involves the application of pressure to specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Transcutaneous Electrical Nerve Stimulation (TENS): TENS involves the use of small electrical currents to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
What are the Challenges Faced by the Postoperative Nausea and Vomiting (PONV) Management Market?
Side effects of antiemetics and expensive nature of PONV management hampering market growth
Patients vary widely in their susceptibility to PONV, and it can be difficult to predict who will experience it. This variability makes it challenging for healthcare providers to tailor treatments to individual patients.
Antiemetic medications are commonly used to manage PONV, but they can have side effects such as sedation, dizziness, and dry mouth. These side effects can be particularly problematic for patients who are already recovering from surgery.
Antiemetic medications can be expensive, and their cost can be a barrier to access for some patients. This can limit the ability of healthcare providers to provide effective PONV management. There is a lack of standardization in the management of PONV, with different healthcare providers using different protocols and medications. This can lead to inconsistency in care and can make it difficult to compare outcomes across different facilities.
Prevention is key to managing PONV, but it can be challenging to identify patients who are at high risk and to implement appropriate preventive measures. This can result in a higher incidence of PONV and increased costs associated with treatment. Some patients and healthcare providers may not be aware of the risks associated with PONV, or may not take it seriously enough. This can lead to inadequate management and can result in unnecessary suffering for patients.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Region-Wise Insights
High Healthcare Expenditure Bolstering Growth of PONV Management Market in North America?
Increasing number of surgeries performed in the region boosting market growth
The North America postoperative nausea and vomiting (PONV) management market is a significant segment of the global PONV management market. North America comprises of developed countries such as the United States and Canada, which have well-established healthcare systems and advanced medical technologies.
The market growth can be attributed to factors such as the increasing number of surgical procedures, rising geriatric population, and the growing prevalence of PONV. The United States dominates the North America PONV management market due to the presence of a large number of hospitals, advanced healthcare infrastructure, and high healthcare expenditure.
According to the Centers for Disease Control and Prevention (CDC), there were around 50 Billion surgeries performed in the United States in 2017, which is expected to increase in the coming years. This high number of surgeries creates a significant demand for PONV management products and services.
The major players in the North America PONV management market include Acacia Pharma Group plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai Co., Ltd., and GlaxoSmithKline plc. These companies are focused on developing innovative products and technologies to improve PONV management, which is expected to drive market growth in the region. Thus, North America is expected to possess 47% market share for PONV management market in 2023.
Increasing prevalence of PONV Propelling Market Growth in Europe?
Technological advancements creating lucrative opportunities for PONV management in Europe
PONV is a common complication of surgery and affects a significant proportion of patients. According to a study published in the European Journal of Anaesthesiology, the incidence of PONV in Europe ranges from 10% to 80% depending on the type of surgery and patient characteristics. The increasing prevalence of PONV is driving the demand for effective PONV management products and services.
The number of surgical procedures performed in Europe is increasing, driven by factors such as the aging population, changing lifestyles, and advancements in medical technology. This creates a significant demand for PONV management products and services.
There have been significant technological advancements in the field of PONV management, such as the development of new antiemetic drugs and the use of non-pharmacological interventions such as acupuncture and acupressure. These advancements are improving the effectiveness of PONV management and are driving market growth.
Governments in Europe are taking initiatives to improve the quality of healthcare and reduce the burden of postoperative complications such as PONV. For example, the European Society of Anaesthesiology has published guidelines for the management of PONV, which are expected to improve the quality of care and drive market growth.
There is growing awareness among patients and healthcare providers about the risks associated with PONV and the importance of effective management. This is driving demand for PONV management products and services. Thus, Europe is expected to possess 43% market share for PONV management market in 2023.
Category-Wise Insights
Access to Medication Increasing Dependability for Management of PONV in Hospital Pharmacies?
Timely administration favoring growth of hospital pharmacies for PONV management
Hospital pharmacies have direct access to a wide range of antiemetic medications that are commonly used for PONV management. This allows healthcare providers to quickly obtain the appropriate medications for patients who are experiencing PONV.
Hospital pharmacists are highly trained professionals who have a thorough understanding of medication management, including the appropriate use of antiemetics. They can provide guidance on medication selection, dosing, and potential drug interactions, which is essential for effective PONV management.
PONV can occur rapidly and may require immediate intervention. Hospital pharmacies are often located within the hospital or adjacent to the surgical suite, which allows for timely administration of antiemetic medications as needed. In addition to medications, hospital pharmacies may have access to specialized equipment such as intravenous pumps, which can be used for the administration of antiemetic medications.
Compliance with regulations: Hospital pharmacies are subject to strict regulatory requirements, which ensures that medications are stored, dispensed, and administered in a safe and appropriate manner. This is particularly important for PONV management, as many antiemetic medications have the potential for adverse effects. Thus, hospital pharmacies are expected to possess 49% market share for PONV management market in 2023.
Market Competition
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
- Acacia Pharma's two primary antiemetic medications for PONV management are Barhemsys® and Amisulpride. Barhemsys® is a selective dopamine D2 and D3 receptor antagonist that is administered intravenously. The drug has been shown to be highly effective in the prevention and treatment of PONV and has received regulatory approval in the United States and Europe.
- Roche has developed a patient-controlled analgesia (PCA) system for PONV management, which delivers a combination of opioids and antiemetic medications through a patient-controlled pump. The PCA system has been shown to be effective in reducing the incidence of PONV and improving patient satisfaction.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 1.17 Billion |
|
Market Value in 2033 |
US$ 3.9 Billion |
|
Growth Rate |
CAGR of 12.8% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Postoperative Nausea and Vomiting (PONV) Management Industry Survey
Treatment Type:
- Serotonin Antagonists
- Steroids
- Dopamine Antagonists
- Neurokinin NK-1 Receptor Antagonists
- Non-pharmacological Treatment
Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies and Drug Stores
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
At what rate did the Postoperative nausea and vomiting (PONV) management market flourish from 2018 to 2022?
From 2018 to 2022, the Postoperative nausea and vomiting (PONV) management market grew at a CAGR of 7.4%
What will be the growth rate of the global Postoperative nausea and vomiting (PONV) management market during the forecast period?
The global Postoperative nausea and vomiting (PONV) management market is expected to grow with a 12.8% CAGR during 2023 to 2033.
What will be the projected market size of the Postoperative nausea and vomiting (PONV) management market by 2033?
As of 2033, the Postoperative nausea and vomiting (PONV) management market is expected to reach US$ 3.9 Billion
Which distribution channel segment is expected to dominate the global Postoperative nausea and vomiting (PONV) management market during 2023?
Hospital pharmacies are expected to hold 49% of the market share in 2023 for Postoperative nausea and vomiting (PONV) management market.
How is the North America Postoperative nausea and vomiting (PONV) management market projected to grow in 2023?
North America is expected to possess 47% market share for Postoperative nausea and vomiting (PONV) management market in 2023.
How is the Europe Postoperative nausea and vomiting (PONV) management market projected to grow in 2023?
Europe Postoperative nausea and vomiting (PONV) management market size is expected to possess 43% market share in 2023.
Table of Content
1. Executive Summary | Postoperative Nausea and Vomiting (PONV) Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 5.3.1. Serotonin Antagonists 5.3.2. Steroids 5.3.3. Dopamine Antagonists 5.3.4. Neurokinin NK-1 Receptor Antagonists 5.3.5. Non-pharmacological Treatment 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 6.3.1. Hospital Pharmacies 6.3.2. Online Pharmacies 6.3.3. Retail Pharmacies and Drug Stores 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment Type 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Type 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Treatment Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Treatment Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Treatment Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment Type 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment Type 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment Type 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment Type 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment Type 15.5.2.2. By Distribution Channel 15.6. United kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment Type 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment Type 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment Type 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment Type 15.9.2.2. By Distribution Channel 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment Type 15.10.2.2. By Distribution Channel 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment Type 15.11.2.2. By Distribution Channel 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment Type 15.12.2.2. By Distribution Channel 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment Type 15.13.2.2. By Distribution Channel 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment Type 15.14.2.2. By Distribution Channel 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment Type 15.15.2.2. By Distribution Channel 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment Type 15.16.2.2. By Distribution Channel 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment Type 15.17.2.2. By Distribution Channel 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment Type 15.18.2.2. By Distribution Channel 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment Type 15.19.2.2. By Distribution Channel 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment Type 15.20.2.2. By Distribution Channel 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment Type 15.21.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment Type 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Acacia Pharma 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. F. Hoffmann-La Roche AG 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Novartis AG 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Ani Pharmaceuticals, Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Camurus AB 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Sanofi S.A. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Helsinn Holding S.A. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Eisai Corporation 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Merck and Co. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. GlaxoSmithKline Corporation 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: South Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Oceania Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment Type, 2023 to 2033 Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment Type, 2023 to 2033 Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: South Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 73: South Asia Market Attractiveness by Treatment Type, 2023 to 2033 Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 76: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 88: East Asia Market Attractiveness by Treatment Type, 2023 to 2033 Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 91: Oceania Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 103: Oceania Market Attractiveness by Treatment Type, 2023 to 2033 Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 106: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 107: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 112: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 115: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 116: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 117: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 118: MEA Market Attractiveness by Treatment Type, 2023 to 2033 Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
